SCTX news sentiment

Scribe Therapeutics (SCTX) Stock Analysis Report | Financials & Insights

Should I buy Scribe Therapeutics Inc. (SCTX)

What date does Scribe Therapeutics Inc.'s (SCTX) report Earnings - Earnings Calendar & Announcement

Scribe Therapeutics (SCTX) awards 14,725 stock options to director Bleharski

Scribe Therapeutics (SCTX) director Joshua Bleharski was granted 14,725 stock options with an exercise price of $15.00 per share, expiring on July 22, 2036. The options will vest in three equal annual installments on July 23 of 2027, 2028, and 2029, contingent on his continued service to the company. This transaction is classified as a compensation award, not a market purchase.

Scribe Therapeutics (SCTX): Avoro group reports 16.37% ownership after IPO

Avoro Capital Advisors LLC, Avoro Ventures LLC, and Behzad Aghazadeh have reported a collective beneficial ownership of 16.37% in Scribe Therapeutics, Inc. (SCTX) common stock following the company's IPO. This stake, totaling 3,088,888 shares, arose from the conversion of Series B preferred stock, purchases during the IPO, and open-market transactions. The entities are subject to customary lock-up agreements and registration rights.

Scribe Therapeutics (SCTX) CFO gets major option grants and family share buys

Scribe Therapeutics CFO David Parrot received significant equity awards, including time-vested and performance-based stock options totaling over 200,000 shares, both priced at $15.00. He also reported indirect open-market purchases of 2,666 common shares for family members at the same price. These transactions follow a prior option grant disclosed in connection with the company's initial public offering.

Scribe Therapeutics (SCTX) CEO receives time- and performance-based option grants

Scribe Therapeutics CEO Benjamin L. Oakes received three option awards for the company's common stock. These include a fully vested grant of 12,969 options on March 13, 2026, and two grants on July 23, 2026: a time-based option for 264,784 shares vesting monthly over four years, and a performance-based option for 429,599 shares contingent on market-based performance criteria. The filing also provides details on vesting schedules, exercise prices, and expiration dates for these grants.

Scribe Therapeutics (SCTX) grants 14,725 options to Aghazadeh and Avoro entities

Scribe Therapeutics (SCTX) ten percent owner Brett Staahl reports stock and option holdings

Scribe Therapeutics (SCTX) ten percent owner Brett Staahl has filed an initial statement of beneficial ownership, reporting 524,336 shares of Common Stock held directly. Additionally, Staahl holds four stock option awards with various exercise prices and expiration dates ranging from 2030 to 2036, covering a total of 26,703 underlying shares. Some of these options are fully vested, while others have a vesting schedule that began on January 1, 2026.

Free cash flow of Scribe Therapeutics Inc. – NASDAQ:SCTX

This article provides a brief mention of the free cash flow for Scribe Therapeutics Inc. (NASDAQ: SCTX) as found on TradingView. It appears to be a financial data point without further analysis or details within the snippet provided. The primary content available is navigational and structural information related to the TradingView platform.

Scribe Therapeutics Inc. (SCTX) Revenue (TTM)

Behzad Aghazadeh Holds Board Seat at Scribe Therapeutics with 16.37% Stake

Behzad Aghazadeh, through funds managed by Avoro, disclosed a 16.37% beneficial stake in Scribe Therapeutics, Inc. (SCTX) via a Schedule 13D filing on July 30, 2026. This stake includes IPO purchases, converted preferred shares, and open-market buys, with Aghazadeh also serving on Scribe's board. The funds hold the shares for investment purposes and have agreed to a 180-day lock-up period, extended until September 28, 2026.

Scribe Therapeutics (SCTX): Avoro group reports 16.37% ownership after IPO

Eli Lilly (SCTX partner) reports 7.36% equity stake in Scribe Therapeutics

Scribe Therapeutics Inc. Revenue Breakdown – NASDAQ:SCTX

Price to earnings ratio of Scribe Therapeutics Inc. – NASDAQ:SCTX

Scribe Therapeutics IPO closes as Sanofi buys 500K shares

Scribe Therapeutics Announces Closing of Initial Public Offering, Full Exercise of Underwriters’ Option to Purchase Additional Shares, and Closing of the Concurrent Private Placement

Scribe Therapeutics Inc. announced the closing of its upsized initial public offering of 9,867,000 shares at $15.00 per share, which included the full exercise of the underwriters' option for additional shares. Concurrently, the company also completed a private placement of 500,000 shares to Sanofi. The total gross proceeds from the IPO and private placement amounted to approximately $155.51 million.

Latham Advises on Scribe Therapeutics’ US$155.51 Million IPO

Latham & Watkins LLP advised the underwriters in Scribe Therapeutics Inc.'s upsized initial public offering, which closed at US$155.51 million. The clinical-stage biotechnology company offered 9,867,000 shares at US$15 per share, including the underwriters' full exercise of their option for additional shares. Scribe Therapeutics' common stock began trading on Nasdaq under the ticker SCTX on July 24, 2026.

Scribe aims for $96M IPO to fund clinical push for lipid-lowering genetic meds

Scribe Therapeutics plans to raise $96 million through an IPO to advance its genetic medicine pipeline, including its lead program STX-1150 for lowering cholesterol, with initial data expected in the first half of 2027. The company will allocate significant funds to clinical development of STX-1150 and other cardiovascular candidates, STX-1400 and STX-1200, which target APOC3 and LPA genes respectively. Big pharmaceutical partners like Sanofi and Eli Lilly are also involved, with Sanofi committing to purchase $7.5 million in stock.

Scribe Therapeutics, Inc. SEC Filing (Jul 24, 2026)

Scribe records upsized $129M IPO to bankroll lipid-lowering genetic meds

Scribe Therapeutics has successfully upsized its IPO, raising $128.7 million to advance its gene-editing pipeline focused on lipid-lowering therapies. The company's lead candidate, STX-1150, targets the PCSK9 gene for cardiovascular disease, with topline data expected in the first half of 2027. Scribe plans to use the proceeds to fund clinical trials for STX-1150, STX-1400, and STX-1200, aiming to offer personalized genetic medicine options for patients.

Scribe Therapeutics Announces Pricing of Upsized Initial Public Offering

ALAMEDA, Calif., July 23, 2026 (GLOBE NEWSWIRE) -- Scribe Therapeutics Inc. (“Scribe Therapeutics”) (Nasdaq: SCTX), a clinical-stage biotechnology company engineering purpose-built in vivo CRISPR technologies designed to extend healthy lifespan through disease prevention and durable therapeutic intervention, today announced the pricing of its upsized initial public offering of 8,580,000 shares of its common stock at the high end of the range at a public offering price of $15.00 per share. The gross proceeds from the offering, before deducting underwriting discounts and commissions and other of

Scribe secures $129M in a rare gene editing IPO

This story was originally published on BioPharma Dive. To receive daily news and insights, subscribe to our free daily BioPharma Dive newsletter. Scribe Therapeutics has raised close to $129 millionin the first initial public offering for a developer of gene editing medicines in more than two years. The startup on Thursday sold 8.58 million shares at $15 apiece, topping projections set earlier this week. Shares will begin trading Friday on the Nasdaq stock exchange under the ticker symbol "SCTX." Biotech IPOs have been on an upswing in 2026. Including Scribe's offering, 14 companies have price